Immunologic significance of HLA class I genes in measles virus-specific IFN-γ and IL-4 cytokine immune responses

Immunogenetics

Volumn 57, Issue 11, 2005, Pages 828-836

  Ovsyannikova, Inna G ^a   Ryan, Jenna E ^a   Vierkant, Robert A ^b   Pankratz, V Shane ^b   Jacobson, Robert M ^a,b   Poland, Gregory A ^a,b  

^a Mayo Vaccine Research Group   (United States)

^b Mayo Clinic   (United States)

Author keywords

HLA class I genes; IFN and IL 4 cytokine responses; Measles vaccine; Measles virus; PBMC; T cells

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA C ANTIGEN; INTERLEUKIN 4; MEASLES MUMPS RUBELLA VACCINE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA POLYMORPHISM; FEMALE; HEREDITY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TH1 CELL; TH2 CELL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GENES, MHC CLASS I; HISTOCOMPATIBILITY TESTING; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; MEASLES VACCINE; MEASLES VIRUS;

MEASLES VIRUS;

EID: 29144435353     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00251-005-0061-6     Document Type: Article

References (45)

1. Arnot D, Lillie JW, Auffray C, Kappes D, Strominger JL (1984) Inter-locus and intra-allelic polymorphisms of HLA class I antigen gene mRNA. Immunogenetics 20:237-252
2. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA (2003) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 52:1-34
3. Cutts FT, Markowitz LE (1994) Successes and failures in measles control. J Infect Dis 170:S32-S41
4. De Groot AS, Saint-Aubin C, Bosma A, Sbai H, Rayner J, Martin W (2001) Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome. Emerg Infect Dis 7:706-713
5. Dhiman N, Ovsyannikova IG, Howe RC, Ryan JE, Jacobson RM, Poland GA (2004) Interleukin-4 induced by measles virus and measles-derived peptides as measured by IL-4 receptor-blocking ELISA. J Immunol Methods 287:217-225
6. Gallagher G, Eskdale J, Jordan W, Peat J, Campbell J, Boniotto M, Lennon GP, Dickensheets H, Donnelly RP (2004) Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 4:615-626
7. Gans HA, Maldonado Y, Yasukawa LL, Beeler J, Audet S, Rinki MM, DeHovitz R, Arvin AM (1999) IL-12, IFN-γ, and T cell proliferation to measles in immunized infants. J Immunol 162:5569-5575
8. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM (2004) Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 190:83-90
9. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A (2000) Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol 61:438-452
10. Griffin DE, Ward BJ (1993) Differential CD4 T cell activation in measles. J Infect Dis 168:275-281
11. Guo SW, Thompson EA (1992) Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48:361-372
12. Herberts CA, Stittelaar KJ, van der Heeft E, van Gaans-Van den Brink J, Poelen MC, Roholl PJ, van Alphen LJ, Melief CJ, de Jong APJ, van Els CA (2001) A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. J Gen Virol 82:2131-2142
13. Höllsberg P (2002) Contribution of HLA class I allele expression to CDS+ T-cell responses against Epstein-Barr virus. Scand J Immunol 55:189-195
14. Howe RC, Dhiman N, Ovsyannikova IG, Poland GA (2005) Induction of CD4 T cell proliferation and Th1-like cytokine responses in vitro to measles virus. Clin Exp Immunol 140:333-342
15. Jacobson RM, Poland GA, Vierkant RA, Pankratz VS, Schaid DJ, Jacobsen SJ, Sauver JS, Moore SB (2003) The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum Immunol 64:103-109
16. Jaye A, Herberts CA, Jallow S, Atabani S, Klein MR, Hoogerhout P, Kidd M, van Els CA, Whittle HC (2003) Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles. J Virol 77:5014-5016
17. MMWR (2003) Update: global measles control and mortality reduction-worldwide, 1991-2001. Morb Mortal Wkly Rep 52:471-475
18. Mongkolsapaya J, Jaye A, Callan MFC, Magnusen AF, McMichael AJ, Whittle HC (1999) Antigen-specific expansion of cytotoxic T lymphocytes in acute measles virus infection. J Virol 73:67-71
19. Nabel GJ, Nabel EG, Yang Z-Y, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 90:11307-11311
20. Nanan R, Carstens C, Kreth HW (1995) Demonstration of virus-specific CD8+ memory Tcells in measles-seropositive individuals by in vitro peptide stimulation. Clin Exp Immunol 102:40-45
21. Naniche D, Garenne M, Rae C, Manchester M, Buchta R, Brodine SK, Oldstone MB (2004) Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J Infect Dis 190:1387-1395
22. Ottenhoff TH, Elferink DG, Hermans J, De Vries RR (1985) HLA class II restriction repertoire of antigen specific T cells. I. The main restriction determinants for antigen presentation are associated with HLA-D/DR and not with DP and DQ. Hum Immunol 13:105-116
23. Ovsyannikova IG, Reid KC, Jacobson RM, Oberg AL, Klee GG, Poland GA (2003) Cytokine production patterns and antibody response to measles vaccine. Vaccine 21:3946-3953
24. Ovsyannikova IG, Jacobson RM, Poland GA (2004a) Variation in vaccine response in normal populations. Pharmacogenomics 5:417-427
25. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA (2004b) The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 65:1506-1515
26. Ovsyannikova IG, Jacobson RM, Ryan JE, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA (2005) HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56:798-807
27. Pabst HF, Spady DW, Carson MM, Stelfox HT, Beeler JA, Krezolek MP (1997) Kinetics of immunologic responses after primary MMR vaccination. Vaccine 15:10-14
28. Pauksen K, Sjolin J, Linde A, Alm G, Andersson B, Lonnerholm G, Ljungman P (1997) Th1 and Th2 cytokine responses after measles antigen stimulation in vitro in bone marrow transplant patients: response to measles vaccination. Bone Marrow Transplant 20:317-323
29. Poland GA (1998) Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am J Hum Genet 62:215-220
30. Poland GA, Jacobson RM (1998) The genetic basis for variation in antibody response to vaccines. Curr Opin Pediatr 10:208-215
31. Poland GA, Jacobson RM, Schaid DJ, Moore SB, Jacobsen SJ (1998) The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine 16:1869-1871
32. Robinson JH, Delvig AA (2002) Diversity in MHC class II antigen presentation. Immunology 105:252-262
33. Rock KL, Gamble S, Rothstein L (1990) Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918-921
34. Schmitt E, Hoehn C, Huels C, Goedert N, Palm N, Rüde ER, Germann T (1994) T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-γ and is inhibited by transforming growth factor-β. Eur J Immunol 24:793-798
35. Sette A, Sidney J (1998) HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10:478-482
36. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201-212
37. van Binnendijk RS, van Baalen CA, Poelen MC, de Vries P, Boes J, Cerundolo V, Osterhaus ADME, Uytdehaag FGCM (1992) Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J Exp Med 176:119-128
38. van Els CA, Herberts CA, van der Heeft E, Poelen MC, van Gaans-van den Brink JA, van der Kooi A, Hoogerhout P, Jan ten Hove G, Meiring HD, de Jong APJ (2000) A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur J Immunol 30:1172-1181
39. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA (2004) HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39:978-988
40. Ward BJ, Griffin DE (1993) Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin Immunol Immunopathol 67:171-177
41. Ward BJ, Johnson RT, Vaisberg A, Jauregui E, Griffin DE (1991) Cytokine production in vitro and the lymphoproliferative defect of natural measles virus infection. Clin Immunol Immunopathol 61:236-248
42. Ward BJ, Boulianne N, Ratnam S, Guiot M-C, Couillard M, De Serres G (1995) Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 172:1591-1595
43. Wong-Chew RM, Beeler JA, Audet S, Santos JI (2003) Cellular and humoral immune responses to measles in immune adults reimmunized with measles vaccine. J Med Virol 70:276-280
44. World Health Organization (2001) Global measles mortality reduction and regional elimination strategic plan 2001-2005 (ref type: report)
45. Young HA, Hardy KJ (1990) Interferon-gamma: producer cells, activation stimuli, and molecular genetic regulation. Pharmacol Ther 45:137-151